Vor Bio Announces Final Two-Year Results From Phase 3 TELIGAN Trial Evaluating Telitacicept In Adults With Iga Nephropathy; TELIGAN Met Stage B Primary Endpoint

뉴스 본문을 불러오고 있어요.

Vor Bio Announces Final Two-Year Results From Phase 3 TELIGAN Trial Evaluating Telitacicept In Adults With Iga Nephropathy; TELIGAN Met Stage B Primary Endpoint | 웨이프 WAPE

Vor Bio Announces Final Two-Year Results From Phase 3 TELIGAN Trial Evaluating Telitacicept In Adults With Iga Nephropathy; TELIGAN Met Stage B Primary Endpoint

기사 요약

관련 종목

댓글 —